NEW YORK – Life science instrumentation company Mobilion Systems said today it has raised $15.4 million in Series A financing.
The Chadds Ford, Pennsylvania-based firm will use the funds to support development of its structure for lossless ion manipulation (SLIM) ion mobility separations technology.
The round was led by Agilent Technologies, with participation from IP Group Inc., Hostplus, Cultivation Capital, and iSelect Fund. In September, Mobilion announced it was partnering with Agilent to implement its SLIM technology on Agilent's QTOF mass spectrometers.
Developed at Pacific Northwest National Laboratory, the SLIM technology extends ion mobility path lengths beyond those allowed by conventional ion mobility spectrometry systems, potentially enabling much more extensive separations, which could aid in a range of mass spec-based research areas, including characterization of biologic drugs and protein biomarker discovery.
"Our products efficiently identify molecules that are indistinguishable with current separation techniques, and we are already working with a number of pharmaceutical collaborators to demonstrate value by addressing the problem of insufficient characterization of biologic therapeutics and by improving the drug development process as a whole," Mobilion CEO Melissa Sherman said in a statement.
Mobilion has said that a beta model of the system will be available in 2020 with a broad commercial launch planned for 2021.